1.Clinical Study on Heat-sensitive Moxibustion in Treating Post-stroke Urinary Incontinence
Yehua BAO ; Jiamei CHU ; Liping LI ; Youhua ZENG ; Yanwu WANG ; Shunxi CHEN ; Xuan DING
Shanghai Journal of Acupuncture and Moxibustion 2016;35(7):786-788
Objective To observe the clinical efficacy of heat-sensitive moxibustion in treating post-stroke urinary incontinence. Method Ninety patients with post-stroke urinary incontinence were randomized into a treatment group and a control group, 45 cases in each group. The treatment group was intervened by heat-sensitive moxibustion at Qihai (CV 6), Guanyuan (CV 4), and Sanyinjiao (SP 6), while the control group was by moxa-box moxibustion. After 4-week treatment, the two groups were compared with each in the incontinence grading and Activities of Daily Living (ADL).Result After treatment, the incontinence grading and ADL scores were significantly changed in both groups (P<0.05). The incontinence grading and ADL scores of the treatment group were significantly different from that of the control group after treatment (P<0.05).Conclusion Heat-sensitive moxibustion can improve the post-stroke urinary incontinence and ADL.
2.Analysis of Ancient Literature and Modern Clinical Application of Tuoli Xiaodusan
Shunxi WANG ; Weilu NIU ; Xuewei LIU ; Jingke GENG ; Mengyue LI
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(8):176-186
Tuoli Xiaodusan is the 65th formula in the Catalogue of Ancient Famous Classical Formulas(First Batch). In this study, the bibliometric method was used to summarize and verify the ancient books about Tuoli Xiaodusan in terms of its historical origin, composition and dosage of the formula, indications, decoction and administration method, and processing, etc. According to the research, there is no definite date of the formation of Tuoli Xiaodusan, the earliest can be traced back to Lizhai Waike Fahui in Ming dynasty, which has been widely circulated, with many versions of prescription composition, and the modern influential version is from Waike Zhengzong in Ming dynasty, which is made up of 12 Chinese herbs including Ginseng Radix et Rhizoma(3.73 g), Chuanxiong Rhizoma(3.73 g), Paeoniae Radix Alba(3.73 g), Astragali Radix(3.73 g), Angelicae Sinensis Radix(3.73 g), Atractylodis Macrocephalae Rhizoma(3.73 g), Poria(3.73 g), Lonicerae Japonicae Flos(3.73 g), Angelicae Dahuricae Radix(1.87 g), Glycyrrhizae Radix et Rhizoma(1.87 g), Gleditsiae Spina(1.87 g), Platycodonis Radix(1.87 g). The herb origins almost follow the 2020 edition of Chinese Pharmacopoeia, except that Angelica dahurica var. formosana is only recommended as the origin of Angelicae Dahuricae Radix, and Glycryyhiza uralensis is only recommended as the origin of Glycyrrhizae Radix et Rhizoma. All the herbs are recommended to be used in the raw products. As for the preparation method, it is recommended to decoct with water, add 400 mL of water, boil until 160 mL, and take 2-3 times a day. The formula has the functions of nourishing Qi and nourishing blood, detoxifying and draining pus, and was mainly used to treat ulcerative diseases with the syndrome of syndrome of healthy Qi deficiency and pathogenic factors excess in ancient times, and in modern times, it is used for a wide range of treatment, involving the skin and soft tissues, bones, digestion and many other systemic diseases, and is also mainly used for syndrome of healthy Qi deficiency and pathogenic factors excess. In this study, the ancient and modern applications of Tuoli Xiaodusan were summarized, and its key information was identified, providing a basis for its wider clinical application, in-depth research and formulation development.
3.Efficacy of mesenchymal stem cells on systemic lupus erythematosus:a meta-analysis.
Shuang LIU ; Yu Long GUO ; Jing Yi YANG ; Wei WANG ; Jian XU
Journal of Peking University(Health Sciences) 2018;50(6):1014-1021
OBJECTIVE:
Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement and several typical autoantibodies. Mesenchymal stem cells (MSC) are multipotent stem cells with low immunogenicity that can differentiate into various kinds of cells, such as bone, cartilage, fat and skin tissue. MSC have immunomodulatory and reparative properties through interactions with immune cells. MSC have been used in the treatment of refractory SLE and lupus nephritis patients for more than ten years. Most clinical studies were self-controlled studies and only a few were randomized controlled trials. The objective of this study was to use meta-analysis method to evaluate the efficacy and safety of MSC treatment in SLE patients.
METHODS:
The PubMed, Cochrane Library, Wanfang and VIP databases were searched for published randomized controlled trials and self-controlled studies before June 1, 2018. The search terms included the Chinese and English versions of mesenchymal stem cells, Mesenchymal Stromal Cells [Mesh], systemic lupus erythematosus, lupus, Lupus Erythematosus, Systemic [Mesh]. Two authors independently screened the literatures, assessed the quality of the studies and collected data according to the inclusion and exclusion criteria. The endpoints were the SLE disease activity index, 24 h urine protein and complement C3. Meta-analysis was performed with the Revman 5.3 software according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standard.
RESULTS:
Eight studies involving 213 patients were included and three of the studies were randomized controlled trials with 66 patients involved. The MSC group showed that the SLE disease activity index decreased significantly [standard mean difference (SMD)=-1.76, 95% confidence interval (CI): -2.00 to -1.51, P<0.001), the 24 h urine protein decreased significantly (SMD=-1.74, 95%CI: -2.46 to -1.03, P<0.001), as well as the complement C3 increased significantly (SMD=1.28, 95%CI: 0.93 to 1.62, P<0.001). Four studies reported adverse events including fever, diarrhea and headache during the infusion.
CONCLUSION
Current evidences showed that MSC could improve the disease activity, proteinuria and hypocomplementemia in SLE patients. Large scale and high-quality randomized controlled trials are required to validate the efficacy and safety of MSC treatment in SLE patients.
Humans
;
Lupus Erythematosus, Systemic/therapy*
;
Lupus Nephritis
;
Mesenchymal Stem Cell Transplantation
;
Mesenchymal Stem Cells
;
Multipotent Stem Cells
;
Proteinuria/therapy*
;
Randomized Controlled Trials as Topic
4.Textual Research on Xianfang Huomingyin from Ancient Literature and Its Modern Clinical Application
Weilu NIU ; Shunxi WANG ; Chengqi LYU ; Xuewei LIU ; Mingsan MIAO ; Jianwei LI ; Gang WANG ; Ningli WANG
Chinese Journal of Experimental Traditional Medical Formulae 2024;30(19):180-189
Xianfang Huomingyin is known as the first prescription of surgery, also known as Shenxian Huomingyin and Zhenren Huomingyin. The earliest one was from Renzhai Zhizhi in the Southern Song dynasty. It was composed of 13 mainstream medicines such as Angelicae Dahuricae Radix, Saposhnikoviae Radix, Paeoniae Radix Rubra, and three modified medicines such as Rhei Radix et Rhizoma, Momordicae Semen and Astragali Radix. It has the effects of clearing heat and detoxifying, detumescence and ulceration, promoting blood circulation and relieving pain, and is mainly used to treat Yang syndrome. In this study, the bibliometrics method was used to systematically study the historical evolution, prescription composition, dosage, indications, decocting methods, administration methods, drug processing and ancient and modern applications of Xianfang Huomingyin. As for the drug origin, pangolin is consistent with the 2015 edition of Chinese Pharmacopoeia, the origins of the remaining drugs are consistent with the 2020 edition of Chinese Pharmacopoeia. According to the ancient and modern dosage conversion, the dosage of each drug is as follows:Angelicae Dahuricae Radix, Paeoniae Radix Rubra, Fritillariae Thunbergii Bulbus, Glycyrrhizae Radix et Rhizoma and Trichosanthis Radix, Olibanum of 4.13 g, Gleditsiae Spina and Myrrha of 2.07 g, Angelicae Sinensis tail(stir-fried with wine) and Citri Reticulatae Pericarpium of 6.2 g, Saposhnikoviae Radix(removing reed) of 2.89 g, pangolin(stir-fried with clam powder) of 4.14 g, Lonicerae Japonicae Flos of 12.39 g, or adding Rhei Radix et Rhizoma of 4.13 g and Momordicae Semen(shelled) of 3.3 g, adding Astragali Radix of 4.13 g for body deficiency. The above medicines were decocted with 450 mL of yellow rice wine to 300 mL, 1 dose for each time, 3 doses for each day, and warmed before or 0.5 h after meals, 1-6 doses, and discontinue medication as soon as get effect. Because this formula is easy to hurt the spleen and stomach, it should not be taken more. In the follow-up, it should be used in conjunction with Tuoli Xiaodusan, and other related symptoms of patients can be further improved through dialectical addition and subtraction. This formula has the efficacy of disinfection and pus discharge, removing blood stasis and relieving pain. All carbuncle gangrene without ulceration at the beginning, and for the empirical and heat syndrome. Modern applications involve more than 200 kinds of diseases with heat syndrome, emergency and excess syndrome as the main syndrome differentiation points in dermatology, peripheral vascular department and other departments. In a word, this paper studies the literature of Xianfang Huomingyin in order to provide a basis for its wider and deeper clinical application and development research.